Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Talus Replacement Registry (3DTalar)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03965143
Recruitment Status : Recruiting
First Posted : May 28, 2019
Last Update Posted : March 31, 2020
Sponsor:
Information provided by (Responsible Party):
Kyle Schweser MD, University of Missouri-Columbia

Brief Summary:
Avascular necrosis of the talus is a difficult problem to manage, especially in the young and healthy. The only option, historically, has been a talectomy and hindfoot fusion. While this is a viable option, it is not without its morbidity. Arthritis of surrounding joints is common, occurring anywhere from 1-10 years after the procedure. This is especially true in younger patients, where loss of motion can be life altering both physically and mentally. The search for alternatives has been limited. Recently, 3D printing has become more ubiquitous and affordable and newer medical alternatives have arisen thanks to this technology. The 3D custom talus is relatively new in the orthopaedic community, but has been used at several centers with good success. It has been shown to re-establish the normal alignment of the foot, preserve motion (with some achieving almost physiologic motion), and allow for almost normal ambulation. However, the data is still limited and further study is necessary. Our facility was recently approved to perform this procedure. Our hypothesis is that custom 3D printed talar body replacements, either used alone or with total ankle replacements, will maintain physiologic motion, have no difference in complications when compared to hindfoot fusions with allograft, lead to good outcome scores and patient satisfaction scores. Patients diagnosed with avascular necrosis of the talus who have already decided to undergo a procedure involving a 3D custom talus as part of their standard care (talar replacement, total ankle/total talus, etc) will be enrolled in the study. Patients will follow standard post-operative protocols and return to clinic at designated time periods (2 weeks, 6 weeks, 3 months, 6 months, 1 year). X-ray evaluation, Range of motion, return to ambulation, walking speed and patient reported outcomes will be evaluated at each visit. Data will then be compared with baseline measurements and use to determine the progression of patients over time after the procedure

Condition or disease Intervention/treatment
Avascular Necrosis of the Talus Device: 3D talar augmentation

Detailed Description:
After patients have undergone a standard of care 3D talar augment procedure they will return to clinic at designated time periods (2 weeks, 6 weeks, 3 months, 6 months, 1 year). X-rays performed as standard of care will be evaluated. Walking speed will be assessed after patient is allowed to bear weight at the same designated time periods reported above. Patients will also answer questions regarding pain (VAS survey), satisfaction (SSQ-8 survey), outcomes utilizing AAOS foot and ankle scores (survey), and self-reported return to unassisted ambulation. Goniometer measurements will be taken in the clinic at all post-operative visits to determine ROM

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 12 Months
Official Title: Talus Replacement Registry
Actual Study Start Date : January 1, 2020
Estimated Primary Completion Date : May 1, 2025
Estimated Study Completion Date : June 1, 2025

Group/Cohort Intervention/treatment
3D talar group
Patients that will undergo a 3D custom talar augment
Device: 3D talar augmentation
Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty




Primary Outcome Measures :
  1. Change Range of motion [ Time Frame: 12 months ]
    Measures with a Goniometer and expressed in degrees

  2. Change in VAS pain Score [ Time Frame: 12 months ]
    The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain."

  3. Change in AAOS foot an ankle score [ Time Frame: 12 months ]
    The AAOS foot and ankle questionnaire is a patient-administrated 25-item survey specifically developed for foot and ankle-related disability. The questionnaire is divided into two scales, the Foot and Ankle Core scale, comprised of 20 questions and the Shoe Comfort Scale with five questions. The questions themselves are distributed among five different categories: Pain (9 items), function (6 items), stiffness and swelling (2 items), giving way (3 items) and shoe comfort (5 items). Answers are then measured on a scale of 1 to 5 or 6, with 1 being the best outcome score.

  4. SSQ-8 satisfaction score [ Time Frame: 12 months ]
    the SSQ-8 (Surgical Satisfaction Score) is a Patient administered 8-item survey designed to asses satisfaction after a surgical procedure. Answers are then measured on a scale of 1 to 5 or 6, with 1 being the best outcome score.

  5. Change in walking speed [ Time Frame: 12 months ]
    Speed will be measured in seconds over a standard distance



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Patients over 18 years of age diagnosed with avascular necrosis of the talar body and amenable to treatment with 3D custom augmentation
Criteria

Inclusion Criteria:

  1. Subjects age 18 years or above at time of screening
  2. Condition satisfies requirement for total talus replacement
  3. Able to consent and participate in the study
  4. No previous history of septic arthritis involving the hindfoot/midfoot
  5. Previous ability to ambulate

Exclusion Criteria:

  1. Active infection, sepsis, osteomyelitis or history of septic arthritis involving the hindfoot/midfoot
  2. Unable to consent or participate in the study secondary to mental status
  3. Condition does not qualify for a total talus replacement
  4. Patients who are pregnant or imprisoned
  5. Planned relocation or unable to return for required follow-up visits

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03965143


Contacts
Layout table for location contacts
Contact: Stacee W Clawson, RN (573) 884-9017 clawsons@health.missouri.edu
Contact: Ennio R Esposito, MD 3468126445 eardvb@health.missouri.edu

Locations
Layout table for location information
United States, Missouri
University of Missouri Recruiting
Columbia, Missouri, United States, 65212
Contact: Ennio R Esposito    573-882-7615    eardvb@health.missouri.edu   
Sponsors and Collaborators
Kyle Schweser MD
Investigators
Layout table for investigator information
Principal Investigator: Kyle M Schweser, MD Assistant Professor Orthopaedic Trauma/Foot and Ankle
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Kyle Schweser MD, Assistant Professor Orthopaedic Trauma/Foot and Ankle, University of Missouri-Columbia
ClinicalTrials.gov Identifier: NCT03965143    
Other Study ID Numbers: 2014893
First Posted: May 28, 2019    Key Record Dates
Last Update Posted: March 31, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The Investigator will maintain all study records according to applicable University regulatory requirement(s). Hard copy records will be retained for at least 7 years after the last clinic follow-up visit at the Missouri Orthopaedic Institute in a locked filing cabinet. Electronic records will be retained for the same amount of time but on secured computers and servers. If the Investigator withdraws from the responsibility of keeping the study records, custody will be transferred to a person willing to accept the responsibility.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Necrosis
Pathologic Processes